论文部分内容阅读
目的比较紫杉醇联合顺铂与奥沙利铂治疗晚期食管癌的临床疗效及安全性。方法选取盐城市射阳县人民医院2013年1月—2015年10月收治的晚期食管癌患者70例,根据化疗方案不同将患者分为PC组38例与PO组32例。PC组患者采取紫杉醇+顺铂方案化疗,PO组采取紫杉醇+奥沙利铂方案化疗,两组患者均持续化疗4个周期。比较两组患者临床疗效及毒副作用发生情况。结果化疗4个周期后,两组患者治疗有效率及治疗控制率比较,差异无统计学意义(P>0.05)。两组患者血象异常、肌肉关节疼痛、肝肾功能损伤发生率比较,差异无统计学意义(P>0.05);PO组患者消化道不适发生率低于PC组(P<0.05)。结论紫杉醇联合顺铂与奥沙利铂治疗晚期食管癌的短期疗效相当,但紫杉醇联合奥沙利铂化疗方案对患者胃肠道影响较小。
Objective To compare the clinical efficacy and safety of paclitaxel plus cisplatin and oxaliplatin in the treatment of advanced esophageal cancer. Methods Seventy patients with advanced esophageal cancer who were treated in Sheyang County People’s Hospital of Yancheng City from January 2013 to October 2015 were divided into 38 cases in PC group and 32 cases in PO group according to different chemotherapy regimens. Patients in PC group were treated with paclitaxel + cisplatin chemotherapy, while those in PO group were treated with paclitaxel + oxaliplatin chemotherapy. Both groups were treated with 4 cycles of chemotherapy. The clinical efficacy and side effects of the two groups were compared. Results After 4 cycles of chemotherapy, there was no significant difference between the two groups in the treatment efficiency and the treatment control rate (P> 0.05). There was no significant difference between the two groups in the incidence of abnormal blood, muscle and joint pain, liver and kidney function (P> 0.05). The incidence of gastrointestinal discomfort in PO group was lower than that in PC group (P <0.05). Conclusions Paclitaxel combined with cisplatin and oxaliplatin in the treatment of advanced esophageal cancer have similar short-term efficacy. However, the combination of paclitaxel and oxaliplatin has little effect on the gastrointestinal tract in patients.